Skip to main content
SpringerLink
Log in

Assessment of Ventricular Remodeling in Heart Failure Clinical Trials

  • Pathophysiology of Myocardial Failure (IS Anand, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Adverse remodeling involves a complicated process of structural and functional changes in the left ventricle (LV). LV remodeling is progressive and, if left unchecked, culminates in heart failure that portends a poor prognosis. Clinical trials in heart failure have employed various techniques to assess ventricular remodeling while focusing on therapeutic-specific strategies to halt or reverse remodeling. These strategies include (1) those designed to reduce wall stress by limiting LV dilatation and reducing LV loading conditions (nitrates and epicardial restraint), (2) those designed to block neurohormonal activation, including angiotensin converting enzyme inhibitors, angiotensin receptor blockers, β-adrenergic receptor blockers, and aldosterone receptor blockers, (3) ionotropic agents/cardiac glycosides, and (4) cardiac resynchronization therapy. Strategies in development include mechanical assist devices and myocardial regeneration. To date, trials have demonstrated a linkage between indices of remodeling and clinical outcomes measures. Indices of remodeling have facilitated identification of targets for novel pharmaceutical agents and new device therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of outstanding importance

  1. Heyndrickx GR, Amano J, Patrick TA, Manders WT, et al. Effects of coronary reperfusion on regional coronary blood flow and function. Circulation. 1985;71:1029–37.

    Article  PubMed  CAS  Google Scholar 

  2. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial function. Circulation. 1993;87:755–63.

    Article  PubMed  CAS  Google Scholar 

  3. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990;81:1161–72.

    Article  PubMed  CAS  Google Scholar 

  4. Erlebacher JA, Weiss JL, Eaton LW, Kallman C, et al. Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study. Am J Cardiol. 1982;49:1120.

    Article  PubMed  CAS  Google Scholar 

  5. Jackson BM, Gorman JH IIISalgo IS, St John Sutton M, Edmunds Jr LH. Increased wall stress due to altered borderzone geometry as assessed by perfusion echocardiography. Am J Physiol. 2003;284:H475–9.

    CAS  Google Scholar 

  6. Mitchell GR, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol. 1992;19:1136–44.

    Article  PubMed  CAS  Google Scholar 

  7. Ross RS, Borg TK. Integrins and the myocardium. Circ Res. 2001;88:1112–9.

    Article  PubMed  CAS  Google Scholar 

  8. Bozurt B, Kribbs SB, Clubb FJ, Michael LH, et al. Patho-physologically relevant concentrations of tumor necrosis factor α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382–91.

    Article  Google Scholar 

  9. Mann DL. Inflammatory mediators and the failing heart: passed, present and the forseeable future. Circ Res. 2002;91:988–98.

    Article  PubMed  CAS  Google Scholar 

  10. Spinale FG. Matrix Metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520–30.

    Article  PubMed  CAS  Google Scholar 

  11. Weber KT. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation. 1997;96:4065–82.

    Article  PubMed  CAS  Google Scholar 

  12. The Digitalis Investigative Group (DIG). The effects of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.

    Article  Google Scholar 

  13. Cohn JN, Archibald DG, Ziesche S, Fransciosa JA, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 1986;314:1547–52.

    Article  PubMed  CAS  Google Scholar 

  14. Cohn JN, Johnson G, Ziesche S, Cobb F, et al. A comparison of enalapril with hydralazine and isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–10.

    Article  PubMed  CAS  Google Scholar 

  15. Power JM, Raman J, Dornom A, Farish SJ, et al. Passive ventricular constraint amends the course of heart failure: a study in an ovine model of dilated cardiomyopathy. Cardiovasc Res. 1999;44:549–55.

    Article  PubMed  CAS  Google Scholar 

  16. Starling RH, Jessup M, Oh JK, Sabbah HN, et al. Sustained benefits of the CorCap support device on left ventricular remodeling: three year follow up results from the Acorn clinical trial. Ann Thorac Surg. 2007;84:1236–42.

    Article  PubMed  Google Scholar 

  17. Sharpe N. Pharmacologic effects on cardiac remodeling. Curr Heart Fail Rep. 2004;1:9–13.

    Article  PubMed  Google Scholar 

  18. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483–90.

    Article  PubMed  CAS  Google Scholar 

  19. Hall JA, Kaumann AJ, Brown MJ. Selective beta-1 adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta-2 adrenoceptors in human atrial myocardium. Circ Res. 1990;66:1610–23.

    Article  PubMed  CAS  Google Scholar 

  20. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larabee P, Bristow MR. Comparative hemodynamic, LV functional, and antiadrenergic effects of chronic treatment with metoprolol vs. carvedilol in the failing heart. Circulation. 1996;94:2817–25.

    Article  PubMed  CAS  Google Scholar 

  21. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17:8–16.

    Article  PubMed  CAS  Google Scholar 

  22. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441–6.

    Article  PubMed  CAS  Google Scholar 

  23. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med. 1996;334:1349–55.

    Article  PubMed  CAS  Google Scholar 

  24. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation. 1996;94:2793–9.

    Article  PubMed  CAS  Google Scholar 

  25. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N; MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;1;94(11):2807–16.

    Google Scholar 

  26. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease: Australia–New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol. 1997;29:1060–6.

    Article  PubMed  CAS  Google Scholar 

  27. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–90.

    Article  PubMed  CAS  Google Scholar 

  28. Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N, CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004;109(2):201–6.

    Article  PubMed  CAS  Google Scholar 

  29. Lowes BD, Gill EA, Abraham WT, et al. The effect of carvedilol on the left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999;83:1201–5.

    Article  PubMed  CAS  Google Scholar 

  30. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.

    Google Scholar 

  31. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial In Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295–302.

    Article  PubMed  CAS  Google Scholar 

  32. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36(7):2072–80.

    Article  PubMed  CAS  Google Scholar 

  33. Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN). Cardiovasc Drugs Ther. 2004;18:57–66.

    Article  PubMed  CAS  Google Scholar 

  34. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P, CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426–35. Epub 2005 Sep 4.

    Article  PubMed  CAS  Google Scholar 

  35. • van de Ven LL, van Veldhuisen DJ, Goulder M, Zilahi Z, Meyer WR, Willenheimer R. The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. Int J Cardiol. 2010;144(1):59–63. This small study addressed the important question of whether initiation of heart failure treatment should begin with ACE-inhibitors first or beta blockers first.

    Article  PubMed  Google Scholar 

  36. Spenser FA, Meyer TE, Gore JM, Goldberg RJ, et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure, the National Registry for Myocardial Infarction. Circulation. 2002;105:2605–10.

    Article  Google Scholar 

  37. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL. Valsartan in Acute Myocardial Infarction trial Investigators (VALIANT). N Engl J Med. 2003;349:1893–906.

    Article  PubMed  CAS  Google Scholar 

  38. Ky B, Plappert T, Kirkpatrick JN, Silvestry FE, et al. Left ventricular remodeling in human heart failure, Quantitative echocardiographic assessment of 1794 patients. Echocardiography. 2012;29(7):758‐65.

    Google Scholar 

  39. Pfeffer MA, Braunwald E, Moye LA, Basta L, et al. On behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669–77.

    Article  PubMed  CAS  Google Scholar 

  40. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, et al. Quantitative two dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation. 1994;89:68–75.

    Article  PubMed  CAS  Google Scholar 

  41. St John Sutton M, Lee D, Rouleau JL, et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107:2577–82.

    Article  PubMed  Google Scholar 

  42. SOLVD Investigators. Effects of enalopril on the development of heart failure in asymptomatic patients with reduced ejection fraction. N Engl J Med. 1992;327:685–91.

    Article  Google Scholar 

  43. SOLVD Investigators. Effect of enalapril onsurvival in patients with reduced ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.

    Article  Google Scholar 

  44. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. The effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–8.

    Google Scholar 

  45. Ambrosioni E, Borghi C. Magnani for the Survival of Myocardial Infarction Long term Evaluation (SMILE) study investigators. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332(2):80–5.

    Article  PubMed  CAS  Google Scholar 

  46. The International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med. 1984;310:9–16.

    Article  Google Scholar 

  47. ISIS-1( First International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet. 1986;2:57–66.

    Google Scholar 

  48. Pitt B, Zannad F, Remme WJ, Cody R, et al. The effect of spironolactone on mortality and morbidity in patients with severe heart failure. N Engl J Med. 1999;341:709–17.

    Article  PubMed  CAS  Google Scholar 

  49. Pitt B, Remme WJ, Zannad F, Neaton J, et al. Eplerinone post AMI heart failure efficacy and survival study: primary results of the EPHESUS trial. N Engl J Med. 2003;348:1309–21.

    Article  PubMed  CAS  Google Scholar 

  50. Mohri S, He K-L, Dickstein M, Mika Y, et al. Cardiac contractility modulation by electric currents applied during the refractory periods. Am J Physiol. 2002;282:H642–7.

    Google Scholar 

  51. Yu CM, Chan JY, Zhang Q, Yip EW, et al. Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:1341–9.

    Google Scholar 

  52. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients in heart failure and intraventricular delay. N Engl J Med. 2001;344:873–80.

    Article  PubMed  CAS  Google Scholar 

  53. Saxon LA, De Marco T, Schafer J, et al. Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation. 2002;105:1304–10.

    Article  PubMed  Google Scholar 

  54. Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation. 2002;105:438–45.

    Article  PubMed  Google Scholar 

  55. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–53.

    Article  PubMed  Google Scholar 

  56. St John Sutton M, Plappert T, Hilpisch KE, Abraham WT, et al. Sustained Reverse left structural remodeling with cardiac resynchronization at one year is a function of etiology. Circulation. 2006;113:266–72.

    Article  Google Scholar 

  57. Chung ES, Leon AR, Tavazzi L, Sun J-P, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608–16.

    Article  PubMed  Google Scholar 

  58. Cleland JG, Daubert JC, Erdmann E, Fremantle N, Cardiac resynchronization –heart failure (CARE-HF) study investigators, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.

    Article  PubMed  CAS  Google Scholar 

  59. •• Moss AJ, Hall WJ, Cannom DS, Klein H, MADIT-CRT trial investigators, et al. Cardiac resynchronization therapy for the prevention of heart failure events. N Engl J Med. 2009;361:1329–38. The MADIT-CRT trials was one of the larger CRT trials with long-term follow up.

    Article  PubMed  Google Scholar 

  60. Linde C, Abraham WT, Gold MR, St John Sutton M, REVERSE (Resynchronization reverses remodeling in systolic left ventricular dysfunction) study group, et al. Randomized trial of resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834–43.

    Article  PubMed  Google Scholar 

  61. Bristow MR, Saxon LA, Boehmer J, Kreuger S, Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) investigator, et al. Cardiac resynchronization therapy with and without implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.

    Article  PubMed  CAS  Google Scholar 

  62. Birks EJ, George RS. Molecular changes occurring during reverse remodelling following left ventricular assist device support. J Cardiovasc Transl Res. 2010 Dec;3(6):635–42. 13

  63. Goldstein DJ, Maybaum S, MacGillivray TE, Moore SA, Bogaev R, Farrar DJ, Frazier OH, HeartMate II Clinical Investigators. Young patients with nonischemic cardiomyopathy have higher likelihood of left ventricular recovery during left ventricular assist device support. J Card Fail. 2012;18(5):392–5.

    Article  PubMed  Google Scholar 

  64. Dandel M, Weng Y, Siniawski H, Potapov E, Drews T, Lehmkuhl HB, Knosalla C, Hetzer R. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation. 2008;118:S94–S105.

    Article  PubMed  Google Scholar 

  65. Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, Webb C, Bougard R, Amrani M, Yacoub MH, Dreyfus G, Khaghani A. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011;123(4):381–90.

    Article  PubMed  CAS  Google Scholar 

  66. • Perin EC, Willerson JT, Pepine CJ, Henry TD, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307:1717–26. This recent trial examined the effect of autologous bone marrow cells injected into the myocardium on LV function and employed LV volume and LVEF assessments as endpoints.

    Article  PubMed  CAS  Google Scholar 

  67. Corsi C, Lang RM, Veronesi F, Weinert L, et al. Volumetric quantification of global and regional left ventricular function from real-time three-dimensional echocardiographic images. Circulation. 2005;112:1161–70.

    Article  PubMed  Google Scholar 

Download references

Disclosure

J. N. Kirkpatrick: none; M. St. John Sutton has received compensation from Medtronic for serving as a consultant and for lectures (including service on speakers bureaus) and is also supported through a grant from Medtronic.

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA

    James N. Kirkpatrick & Martin St. John Sutton

Authors
  1. James N. Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin St. John Sutton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin St. John Sutton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirkpatrick, J.N., St. John Sutton, M. Assessment of Ventricular Remodeling in Heart Failure Clinical Trials. Curr Heart Fail Rep 9, 328–336 (2012). https://doi.org/10.1007/s11897-012-0116-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-012-0116-6

Keywords

Search

Navigation